Back | Next |
home / stock / ifrx / ifrx message board
Subject | By | Source | When |
---|---|---|---|
$IFRX is going to leap fast forward to | dinogreeves | investorshub | 04/08/2023 4:11:27 AM |
Incredible dip buy opportunity: 2 more buy ratings today. That | Hercules1 | investorshub | 04/06/2023 5:20:19 PM |
How is the no more all bold thing | Golden Cross | investorshub | 04/06/2023 4:39:16 PM |
I disagree they always eventually do | the_stockoracle | investorshub | 04/06/2023 4:28:22 PM |
Churning nicely today | Golden Cross | investorshub | 04/06/2023 3:54:56 PM |
$IFRX$$$ SELLING IS DONE..ABOUT TO EXPLODE...$50.00+ VERY POSSIBLE.. | halbroke1 | investorshub | 04/06/2023 2:37:21 PM |
agree | peterus | investorshub | 04/06/2023 2:19:32 PM |
and up too. only watching for.. | gail | investorshub | 04/06/2023 2:17:19 PM |
could but not all gaps close | peterus | investorshub | 04/06/2023 2:16:47 PM |
All gaps have to be closed will go | the_stockoracle | investorshub | 04/06/2023 2:15:52 PM |
bought the dipp 5.46s | peterus | investorshub | 04/06/2023 2:11:00 PM |
see how fast it go down | peterus | investorshub | 04/06/2023 2:10:14 PM |
znewcar1: $IFRX 61% v94,4M c6.10 f44,7M H7.25 ML1.57 gapNgo to HOD flushed | znewcar1 | investorshangout | 04/05/2023 9:33:54 PM |
znewcar1: Off the HOD Bounced dipped | znewcar1 | investorshangout | 04/05/2023 3:35:10 PM |
znewcar1: $IFRX HOD7.25 | znewcar1 | investorshangout | 04/05/2023 2:14:56 PM |
znewcar1: $IFRX 74% v33,0M c6.58 f44,7M H6.58 Thin over $7 open sky >9.7 Established: 03/03/2020 3:4 | znewcar1 | investorshangout | 04/05/2023 2:10:03 PM |
znewcar1: $IFRX 82% v10,2M Hod 3.92 @3.731 f44,7M ML1.57 LOD1.95 then pop >2.5 | znewcar1 | investorshangout | 04/04/2023 7:46:06 PM |
znewcar1: lod2.5 $IFRX S2? | znewcar1 | investorshangout | 01/13/2023 5:46:27 PM |
znewcar1: $IFRX 27% v1,16M c2.70 f44,2M H2.74 ML2 YL2.08 gapNgo | znewcar1 | investorshangout | 12/22/2022 2:11:01 AM |
znewcar1: IFRX 38% v8,6M c1.92 f44,2M H2.14 ML.94 HOD S1.81 | znewcar1 | investorshangout | 07/26/2022 9:24:07 PM |
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...